- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04840160
Influence of Tart Cherry Juice Intervention on Vascular Function
April 8, 2021 updated by: Northumbria University
Influence of Tart Cherry Juice Intervention on Vascular Function and the Urinary Metabolite; a Preliminary Study to Inform Study Design
Diets containing fruit rich in anthocyanins have been shown (in meta-analyses) to be beneficial for health, but intervention trials have shown inconsistent results.
In this preliminary study we want to investigate the influence of a tart-cherry juice intervention on vascular function and explore metabolite profiles that may offer insight into their mechanism of action
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Cardiovascular disease (CVD) is the primary cause of morbidity and mortality.
Tart cherries (TC) can positively impact major risk factors of CVD, activities thought to be related to their phytochemical content.
However, data from human trials is less clear.
TC have been shown to reduce systolic blood pressure (SBP) after acute, short-term and chronic intake, and to improve vascular dysfunction, presumably due to their antioxidant and anti-inflammatory activities.
Other studies have not shown benefits of TC on SBP or vascular function and studies are difficult to interpret with different populations, dosing and durations being used as well as a lack of understanding for any underlying mechanisms.
To account for the latter, the use of metabolomics has become increasingly popular in nutritional research.
Therefore, the aim of this preliminary study was to characterise the effects of TC supplementation on vascular function with a 4-week intervention and explore if metabolomics can provide mechanistic evidence and this will inform for future chronic studies with TC juice.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Newcastle Upon Tyne, United Kingdom, NE1 7ST
- Northumberland Building
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- aged 19-40
- no diagnosed issues with the ability to consume fruit juice
- no known food intolerances to fruits
Exclusion Criteria:
- participants that are cigarette smokers
- participants diagnosed with hypertension
- participants diagnosed with any form of cardiometabolic diseases
- participants that require any prescribed prescriptions excluding the contraceptive pill
- participants that are regular consumers of cherries (>100 g/d)
- participants that consume any antioxidant supplements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants supplied with 30 ml of a low fruit (<1%) cordial mixed with maltodextrin and protein diluted in 100 ml water twice daily, once in the morning and evening.
|
A tart cherry juice placebo
|
Experimental: Cherry juice
Participants supplied with 30 ml of a tart cherry juice concentrate (CherryActive, United Kingdom; (containing 36.8 mg of anthocyanins) diluted in 100 ml of water twice daily, once in the morning and evening.
|
A tart cherry juice intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Systolic and diastolic blood pressure
Time Frame: Change in blood pressure following 4 weeks intervention
|
Measurement of systolic and diastolic blood pressure before and after the intervention
|
Change in blood pressure following 4 weeks intervention
|
Arterial pulse wave velocity
Time Frame: Change in pulse wave velocity following 4 weeks intervention
|
Measurement of pulse wave velocity before and after the intervention
|
Change in pulse wave velocity following 4 weeks intervention
|
Digital volume pulse
Time Frame: Change in digital volume pulse following 4 weeks intervention
|
Measurement of digital volume pulse before and after the intervention
|
Change in digital volume pulse following 4 weeks intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolomics
Time Frame: Changes to urinary metabolite profiles following 4 weeks intervention
|
Ion intensities of ca 5000 metabolites in urine samples before and after the intervention
|
Changes to urinary metabolite profiles following 4 weeks intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2016
Primary Completion (Actual)
August 1, 2017
Study Completion (Actual)
August 1, 2019
Study Registration Dates
First Submitted
April 6, 2021
First Submitted That Met QC Criteria
April 8, 2021
First Posted (Actual)
April 9, 2021
Study Record Updates
Last Update Posted (Actual)
April 9, 2021
Last Update Submitted That Met QC Criteria
April 8, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- lucymurray2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Research data will be shared on request
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Disturbance
-
The Swedish School of Sport and Health SciencesActive, not recruiting
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
University of TorontoCanadian Institutes of Health Research (CIHR)RecruitingSedentary Behavior | Metabolic DisturbanceCanada
-
Appalachian State UniversityRecruitingGastrointestinal Dysfunction | Metabolic DisturbanceUnited States
-
University of TorontoWomen's College HospitalCompleted
-
University of TorontoCompletedMetabolic DisturbanceCanada
-
Northumbria UniversityUnknownMetabolic Disturbance | Dietary ExposureUnited Kingdom
-
University of NottinghamCompletedObesity | Metabolic DisturbanceUnited Kingdom
-
University of TorontoActive, not recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States